Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Rovaris M, Comi G, Ladkani D, Wolinsky JS, Filippi M, and the European/Canadian Glatiramer Acetate Study Group. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.AJNR Am J Neuroradiol 24: 75–81, 2003.
2. Stoof JC, Winogradzka A, van Muiswinkel FL, Wolters EC, Voorn P, Groenewegen HJ et al. Leads for the development of neuroprotective treatment in Parkinson’s disease and brain imaging methods for estimating treatment efficacy.Eur J Pharmacol 375: 75–86, 1999.
3. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer’s disease.Neurobiol Aging 19: 109–116, 1998.
4. Morrish PK, Sawle GV, Brooks DJ. An18F dopa-PET and clinical study of the rate of progression in Parkinson’s Disease.Brain 119: 585–591, 1996.
5. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?JAMA 282: 790–795, 1999.
Cited by
281 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献